Physician profile
Theresia Roach
NPI 1851789598
$855.46
in general payments reported to CMS, 2019-2025
11 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.42 · 2022: $55.80 · 2023: $308 · 2024: $312 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $323.77 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $143.80 | 2023-2025 | Collagenase Santyl |
| Janssen Pharmaceuticals, INC | $111.22 | 2022-2023 | Xarelto |
| Abbvie INC. | $71.65 | 2023-2025 | |
| Solventum Corporation | $57.46 | 2024-2025 | Activ.A.C., Promogran Prisma, 3m Coban |
| Reprise Biomedical, INC. | $35.06 | 2024 | Miro3d |
| Genentech USA, INC. | $34.44 | 2021-2022 | |
| Atricure, INC. | $33.67 | 2023 | |
| Merck Sharp & Dohme LLC | $16.13 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.95 | 2024 | Nuzyra |
| Molnlycke Health Care US, LLC | $12.31 | 2024 | Mepilex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresia Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.